Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study
This review (16 publications, including 8 original studies [n=1478]), could not identify robust evidence on the prognostic accuracy of the biomarker-stratification tools, IBDX & PredictSURE-IBD. Given the lack of evidence, the cost model mainly consisted of a theoretical exercise
Source:
National Institute for Health Research
SPS commentary:
Identifying people with Crohn’s disease who might develop complications or need surgery could help determine which treatment might work best for a patient, with the goal of reducing the number of relapses and the risk of surgery in the longer term. NICE diagnostics guidance is under development for PredictSURE IBD and IBDX to guide treatment of Crohn’s disease. NICE also published a Medtech Innovation Briefing on the use of PredictSure-IBD for inflammatory bowel disease prognosis in March 2019.